Nov 14, 2023
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 14, 2023-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as
Aug 14, 2023
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 14, 2023-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023 , and recent business highlights.
Jun 23, 2023
SAN DIEGO --(BUSINESS WIRE)--Jun. 23, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced it will be added to the Russell 2000® and
Apr 14, 2023
SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D.
Mar 27, 2023
SAN DIEGO --(BUSINESS WIRE)--Mar. 27, 2023-- As previously announced on March 21, 2023 , Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the closing of its business combination with